Alex's Lemonade Stand Foundation

Wilms Tumor Impact Report

Alex's Lemonade Stand
Foundation for Childhood Cancer™

AlexsLemonade.org

Alex's Lemonade Stand Foundation (ALSF) emerged from the front yard lemonade stand of 4-year-old Alexandra “Alex” Scott, who was fighting cancer and wanted to raise money to find cures for all children with cancer. By the time Alex passed away at the age of 8, she had raised $1 million. Since then, the Foundation bearing her name has evolved into a worldwide fundraising movement and the largest independent childhood cancer charity in the U.S. ALSF is a leader in funding pediatric cancer research projects across the globe and providing programs to families affected by childhood cancer.

With Gratitude

Dear Friend,

All of us at Alex's Lemonade Stand Foundation are sending a heartfelt thank you for supporting Alex's mission of curing childhood cancers like Wilms tumor through the discovery of new and safer treatments.

Your generosity empowers scientists to gather crucial preliminary data, publish breakthrough findings, and advance innovative treatment approaches. Because of you, we're moving closer to a future where no child faces Wilms tumor.

It's an honor to stand beside you in this fight. Your commitment fuels lifesaving progress. If there's ever anything we can do for you, please let the ALSF team know.

Until there are cures,

Liz + Jay

Liz & Jay Scott
Alex's Parents & Co-Executive Directors
Alex's Lemonade Stand Foundation

ALSF

Thanks to Supporters Like You

15

Wilms tumor projects (and counting) have been funded

> “ALSF funding was absolutely essential to make this project happen. There are not many funding instruments available to support projects of this scale.”
>
> — Dr. Florian Halbritter,
> St. Anna Children's Cancer Research Institute

> “Early career support for pediatric oncology physician-scientists is a critical lifeline during an incredibly vulnerable time in our careers. The support of ALSF has been and continues to be absolutely essential in making better therapies available faster for pediatric cancer patients.”
>
> — Dr. Leo Wang,
> City of Hope

ALSF

Meet a **Wilms Tumor Hero**

Name: Georgia

Loves: Princesses, Disney World, and hugs

Georgia is the friendliest kid her mom knows, the kind of little girl who makes instant best friends, gives the biggest hugs, and lights up a room with princess talk and Disney dreams. One Easter morning, her mom, Gina noticed pink in Georgia's diaper and rushed her to the ER. Within an hour, an ultrasound revealed a three-inch mass on her kidney. She was transferred by ambulance to a children's hospital, where doctors diagnosed her with stage 1 Wilms tumor.

Surgeons removed the tumor along with Georgia's right kidney, and she started a 19-week chemotherapy plan. Through every blood draw and clinic day, Georgia showed a quiet kind of bravery, smiling for the nurses, bouncing back to play, and proving tougher than cancer expected. Not long after, she rang the bell to celebrate the end of treatment, a moment that marked the close of a harrowing chapter and the start of a brighter one.

Along the way, Gina discovered a community in Alex's Lemonade Stand Foundation, proof, she says, that so many people are in this fight for a cure. When she can, she supports ALSF fundraisers because they bring her hope and help push research forward for all kids. Today, Georgia's story is one of strength, joy, and momentum: a sunshine personality, a warrior's spirit, and a family looking ahead with gratitude. Gina's wish is simple and sweeping, that Georgia's life stays full, happy, and cancer-free, and that, one day every child's treatment success rate reaches 100 percent.

Research Spotlight: New Projects in Wilms Tumor

Towards LNP Vaccine Immune-Interception for Childhood Cancer Predisposition Syndromes

Uri Tabori, MD, The Hospital for Sick Children (SickKids)

Some children inherit genetic syndromes such as Li-Fraumeni or mismatch repair deficiency. These genetic syndromes put children at an extremely high risk of developing cancer. These cancers are often resistant to standard treatments, making prevention especially important. Dr. Uri Tabori and Dr. David Malkin at The Hospital for Sick Children in Toronto are exploring a groundbreaking idea: using a personalized cancer vaccine to stop and block cancer before it even starts. Their research focuses on “immune interception,” teaching the immune system to recognize and eliminate early cancer cells by targeting unique mutated proteins known as neoantigens. Using mRNA technology, they hope to prevent tumor development all together. If successful, this approach could revolutionize and change the future of care for children with cancer predisposition syndromes and potentially extend to even more pediatric cancers.

ROR2 as a candidate immunotherapeutic target in Wilms Tumor

Maria Evancho, MS, Children’s Hospital of Philadelphia

Anaplastic Wilms tumor is difficult to cure because it grows aggressively and doesn’t respond well to current therapies. This makes finding safer, more effective treatments a critical need. Their lab at CHOP uses advanced techniques to study proteins on the surface of cancer cells that could be targeted by immunotherapy. Immunotherapy has shown remarkable success in curing certain childhood blood cancers. They previously applied this approach to neuroblastoma, and are now using it to study Wilms Tumor. They have identified a particular protein that is abundant on Wilms tumor cells but not normal tissues. With a POST Grant from ALSF, Maria studied if this protein is present on Wilms tumor cells, whether it plays a role in their growth and what happens when the protein is removed or blocked. Ultimately, their work aims to create a new, less toxic treatment option for children with high-risk kidney cancers, giving them a better chance at survival.

Thank You

for all you do to help kids with cancer!